Downloads: 288

Files in This Item:
File Description SizeFormat 
s00280-009-1239-7.pdf189.36 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYanagihara, Kazuhiroen
dc.contributor.authorYoshimura, Kenichien
dc.contributor.authorNiimi, Miyukien
dc.contributor.authorYasuda, Hiroyasuen
dc.contributor.authorSasaki, Takahikoen
dc.contributor.authorNishimura, Takafumien
dc.contributor.authorIshiguro, Hiroshien
dc.contributor.authorMatsumoto, Shigemien
dc.contributor.authorKitano, Toshiyukien
dc.contributor.authorKanai, Masashien
dc.contributor.authorMisawa, Akikoen
dc.contributor.authorTada, Harueen
dc.contributor.authorTeramukai, Satoshien
dc.contributor.authorMio, Tadashien
dc.contributor.authorFukushima, Masanorien
dc.contributor.alternative柳原, 一広ja
dc.date.accessioned2010-10-28T00:16:22Z-
dc.date.available2010-10-28T00:16:22Z-
dc.date.issued2010-10-
dc.identifier.citationAA00598397-
dc.identifier.issn0344-5704-
dc.identifier.urihttp://hdl.handle.net/2433/129639-
dc.description.abstractPURPOSE: The purpose of the present phase II study was to evaluate both the efficacy and toxicity of the combination of S-1 and docetaxel in previously treated patients with locally advanced or metastatic non-small cell lung cancer. METHODS: Thirty-eight previously treated patients with non-small cell lung cancer were treated with S-1 (80 mg/m(2), days 1-14, oral) and docetaxel (40 mg/m(2), day 1, intravenous) every 3 weeks. RESULTS: No complete response was observed, and seven patients had a partial response, yielding an overall response rate of 18.4% (95% CI, 7.7-34.3%). The median overall survival time and 1-year overall survival rate were 16.1 months and 60%, respectively. The median progression-free survival time was 4.4 months. Myelosuppression was the main toxicity with grade 3 or 4 neutropenia and leukopenia in 50 and 21%, respectively. There was no irreversible toxicity in this study. CONCLUSIONS: The combination of S-1 and docetaxel is well tolerable and has substantial activity for patients with locally advanced or metastatic non-small cell lung cancer. A phase III trial comparing docetaxel with or without S-1 would warrant further investigation.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer-Verlagen
dc.rightsThe original publication is available at www.springerlink.comen
dc.rightsThis is not the published version. Please cite only the published version.en
dc.rightsこの論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。ja
dc.subjectNon-small cell lung canceren
dc.subjectPhase II studyen
dc.subjectDocetaxelen
dc.subjectS-1en
dc.subjectSecond-line chemotherapyen
dc.subjectThird-line chemotherapyen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/adverse effectsen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subject.meshCarcinoma, Non-Small-Cell Lung/drug therapyen
dc.subject.meshCarcinoma, Non-Small-Cell Lung/pathologyen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshDrug Combinationsen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshLeukopenia/chemically induceden
dc.subject.meshLung Neoplasms/drug therapyen
dc.subject.meshLung Neoplasms/pathologyen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshNeoplasm Metastasisen
dc.subject.meshNeutropenia/chemically induceden
dc.subject.meshOxonic Acid/administration & dosageen
dc.subject.meshSurvival Rateen
dc.subject.meshTaxoids/administration & dosageen
dc.subject.meshTegafur/administration & dosageen
dc.subject.meshTreatment Outcomeen
dc.titlePhase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleCancer chemotherapy and pharmacologyen
dc.identifier.volume66-
dc.identifier.issue5-
dc.identifier.spage913-
dc.identifier.epage918-
dc.relation.doi10.1007/s00280-009-1239-7-
dc.textversionauthor-
dc.identifier.pmid20069422-
dcterms.accessRightsopen access-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.